Prestige Consumer Healthcare (NYSE:PBH) Cut to “Hold” at StockNews.com

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a research report report published on Thursday.

Several other analysts have also recently commented on PBH. Jefferies Financial Group reiterated a “hold” rating and issued a $76.00 price target (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research note on Tuesday, September 24th. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 target price on the stock. in a report on Monday, December 9th. Finally, DA Davidson restated a “buy” rating and issued a $95.00 target price on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Three analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $85.25.

Prestige Consumer Healthcare Stock Up 0.4 %

PBH opened at $78.58 on Thursday. The company has a debt-to-equity ratio of 0.61, a quick ratio of 2.10 and a current ratio of 3.56. Prestige Consumer Healthcare has a fifty-two week low of $58.22 and a fifty-two week high of $86.36. The firm’s fifty day moving average is $80.52 and its 200 day moving average is $74.53. The stock has a market cap of $3.88 billion, a price-to-earnings ratio of 19.12, a price-to-earnings-growth ratio of 2.08 and a beta of 0.51.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The company had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the previous year, the company earned $1.07 EPS. Prestige Consumer Healthcare’s revenue for the quarter was down .9% on a year-over-year basis. On average, sell-side analysts forecast that Prestige Consumer Healthcare will post 4.44 earnings per share for the current fiscal year.

Insider Activity at Prestige Consumer Healthcare

In related news, EVP Adel Mekhail sold 9,063 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $82.00, for a total transaction of $743,166.00. Following the transaction, the executive vice president now directly owns 18,365 shares in the company, valued at approximately $1,505,930. This represents a 33.04 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider William P’pool sold 8,987 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $81.85, for a total transaction of $735,585.95. Following the transaction, the insider now owns 20,058 shares in the company, valued at $1,641,747.30. The trade was a 30.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 38,810 shares of company stock worth $3,187,300. Insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Prestige Consumer Healthcare

A number of hedge funds have recently added to or reduced their stakes in PBH. Quest Partners LLC grew its stake in Prestige Consumer Healthcare by 2,826.7% in the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock worth $30,000 after acquiring an additional 424 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Prestige Consumer Healthcare by 562.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock worth $35,000 after acquiring an additional 433 shares in the last quarter. nVerses Capital LLC grew its stake in Prestige Consumer Healthcare by 200.0% in the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after acquiring an additional 400 shares in the last quarter. Huntington National Bank grew its stake in Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock worth $46,000 after acquiring an additional 181 shares in the last quarter. Finally, International Assets Investment Management LLC grew its stake in Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock worth $83,000 after acquiring an additional 1,138 shares in the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.